Clinical Trial Update: Study To Evaluate The Efficacy And Safety Of PH-797804 For 12 Weeks In Adults With Moderate To Severe Chronic Obstructive Pulmonary Disease (COPD) Taking Salmeterol Xinafoate/Fluticasone Propionate Combination [Phase 2]

View source ↗

Summary

A Phase 2 study evaluating the efficacy and safety of PH-797804 in adults with moderate to severe chronic obstructive pulmonary disease who are taking a salmete…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Chronic Obstructive Pulmonary Disease

Drugs mentioned

• PH-797804
• Salmeterol Xinafoate/Fluticasone Propionate Combination (salmeterol xinafoate and fluticasone propionate)

Snippet

Sponsor: Pfizer | Conditions: Pulmonary Disease, Chronic Obstructive | Phase 2 | Status: COMPLETED